GlassScriptPhysician profile
Stephanie A Knapp
NPI 1386607208
$2,986.46
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $783 · 2020: $467 · 2021: $704 · 2022: $638 · 2023: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $395.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $394.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $711.80 | 2019-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Kaleo, INC. | $290.79 | 2019-2023 | Auvi-Q |
| Genentech USA, INC. | $263.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $207.74 | 2020-2023 | Takhzyro |
| Astrazeneca Pharmaceuticals LP | $184.95 | 2019-2023 | Tezspire |
| Abbvie INC. | $174.10 | 2021-2023 | |
| Optinose US, INC. | $162.58 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $146.42 | 2019-2023 | |
| Aimmune Therapeutics, INC. | $136.00 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.76 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $97.87 | 2019-2020 | |
| Genzyme Corporation | $90.50 | 2020-2023 | |
| Teva Pharmaceuticals USA, INC. | $86.77 | 2020-2021 | |
| Covis Pharma Gmbh | $84.58 | 2021 | |
| Pfizer INC. | $67.62 | 2019-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $67.61 | 2019-2022 | |
| Amgen INC. | $25.47 | 2021 | |
| Phadia US INC. | $19.03 | 2022 | |
| Hikma Pharmaceuticals USA | $15.81 | 2023 | Ryaltris |
| Biocryst US Sales Co., LLC | $14.12 | 2023 | Orladeyo |
| Blueprint Medicines Corporation | $13.80 | 2023 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Knapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.